In this study, investigators estimated rates of remission and response in patients with active Crohn's disease (CD) who were receiving placebo. The team aimed to identify factors influencing these rates.
The team performed a systematic review and meta-analysis of trials that evaluated therapies for active CD. The team used MEDLINE to identify trials published between 1966 and 2001.
The investigators found that the pooled estimates of the placebo rates of remission and response were 18% and 19%, respectively.
In multivariate models, study duration, number of study visits, and entry Crohn’s Disease Activity Index score were important predictors of the placebo remission rate.
|Rates of remission and response were 18% and 19%, respectively.|
The team determined that factors influencing placebo response rates were similar to those affecting remission rates.
The absolute benefit of active treatment beyond placebo was generally larger when outcome was measured by response than remission.
Dr Chinyu Su's team concluded, "Placebo remission and response rates in placebo controlled, randomized clinical trials for active CD are variable".
"Study duration, number of study visits, and disease severity at entry have a large influence on placebo remission rates".